ArticleMolecular neuropsychiatry2018
Interleukin-17 Alteration in First-Episode Psychosis: A Meta-Analysis.
Article in Molecular neuropsychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- The Interrelationships between Cytokines and Schizophrenia: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.International journal of molecular sciences · 2023Pooled it
- Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders.Translational psychiatry · 2020Pooled it
- Plasma IL-17A, IFN-γ, and MIP-3α profiles are associated with clinical stage transition in first-episode psychosis.Brain, behavior, & immunity - health · 2026Article
- Potential biomarkers differentiating major depression from bipolar disorder depressive episodes by Olink Proteomics.BMC psychiatry · 2026Article
- The emerging role of T cells in depression.Frontiers in psychiatry · 2026Review
- Peripheral inflammation and neurocognitive functioning in early psychosis: Specific associations of TNF-α and IL-6 with social cognition.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Inflammatory markers and cognitive deficits in first-episode psychoses - A cross-sectional study.Indian journal of psychiatry · 2025Article
- Viral infections in etiology of mental disorders: a broad analysis of cytokine profile similarities - a narrative review.Frontiers in cellular and infection microbiology · 2024Review
- Evidence of innate immune dysfunction in first-episode psychosis patients with accompanying mood disorder.Journal of neuroinflammation · 2022Article
- Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia.International journal of molecular sciences · 2022Review
- Delirium due to hip fracture is associated with activated immune-inflammatory pathways and a reduction in negative immunoregulatory mechanisms.BMC psychiatry · 2022Article
- IL-17 and TNF-β: Predictive biomarkers for transition to psychosis in ultra-high risk individuals.Frontiers in psychiatry · 2022Article
- Differences in inflammatory marker profiles and cognitive functioning between deficit and nondeficit schizophrenia.Frontiers in immunology · 2022Article
- The Role of Cytokines in the Pathogenesis of Schizophrenia.Journal of clinical medicine · 2021Review
- Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study.Schizophrenia bulletin open · 2021Article
- Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment.Frontiers in psychiatry · 2021Review
- Type 17 Immune Response Facilitates Progression of Inflammation and Correlates with Cognition in Stable Schizophrenia.Diagnostics (Basel, Switzerland) · 2020Article
- Reduced regulatory T cells with increased proinflammatory response in patients with schizophrenia.Psychopharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is accompanied with central nervous system and peripheral immune system imbalances. Interleukin-17 (IL-17) is implicated in various immune and inflammatory processes. Aberrant levels of IL-17 have been reported in patients with schizophrenia, whereas the results are not consistent. To clarify the relationship between IL-17 and schizophrenia, we performed a meta-analysis in this study. We carried out a structured literature search in PubMed and Embase database up to April 16, 2017, and retrieved all eligible case-control studies according to the inclusion criteria. Finally, a total of 313 patients with drug-naïve first-episode psychosis and 238 healthy control subjects from 5 studies were included in our meta-analysis. There were no significant differences between first-episode psychosis patients and healthy controls with respect to the levels of IL-17 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.